BACKGROUND: Thrombocytopenia has been reported to be associated with efalizumab therapy, but has only sporadically been reported with other anti-tumor necrosis factor alfa (TNF-alpha) agents. OBJECTIVE: To describe the frequency of thrombocytopenia in a cohort of patients who underwent biological therapies for psoriasis. METHODS: This was a retrospective observational study of 93 patients. RESULTS: One hundred eighteen courses of biological therapies were administered to 93 patients. Four of 67 patients who received anti-TNF-alpha agents developed drug-induced thrombocytopenia during treatment, compared with none of the 51 patients receiving efalizumab therapy. The platelet count recovered after suspension of anti-TNF-alpha agents in 3 patients and relapsed after re-exposure in two patients. The overall estimated frequency of thrombocytopenia in our cohort was 4.30% (95% confidence interval [CI], 0% to 6.2%). LIMITATIONS: These findings should be validated in larger studies. CONCLUSIONS: Drug-induced thrombocytopenia is a potential side effect of anti-TNF-alpha agents. Immediate monitoring of platelet counts is recommended if autoimmunity is suspected.
BACKGROUND:Thrombocytopenia has been reported to be associated with efalizumab therapy, but has only sporadically been reported with other anti-tumornecrosis factor alfa (TNF-alpha) agents. OBJECTIVE: To describe the frequency of thrombocytopenia in a cohort of patients who underwent biological therapies for psoriasis. METHODS: This was a retrospective observational study of 93 patients. RESULTS: One hundred eighteen courses of biological therapies were administered to 93 patients. Four of 67 patients who received anti-TNF-alpha agents developed drug-induced thrombocytopenia during treatment, compared with none of the 51 patients receiving efalizumab therapy. The platelet count recovered after suspension of anti-TNF-alpha agents in 3 patients and relapsed after re-exposure in two patients. The overall estimated frequency of thrombocytopenia in our cohort was 4.30% (95% confidence interval [CI], 0% to 6.2%). LIMITATIONS: These findings should be validated in larger studies. CONCLUSIONS: Drug-induced thrombocytopenia is a potential side effect of anti-TNF-alpha agents. Immediate monitoring of platelet counts is recommended if autoimmunity is suspected.
Authors: Violetta S Gogoleva; Kamar-Sulu N Atretkhany; Arina P Dygay; Taisiya R Yurakova; Marina S Drutskaya; Sergei A Nedospasov Journal: Front Immunol Date: 2021-05-13 Impact factor: 7.561
Authors: Mohamed H Bikhet; Christophe Hansen-Estruch; Mariyam Javed; Dalis E Collins; Jeremy B Foote; David Ayares; Hidetaka Hara; David K C Cooper Journal: Immun Inflamm Dis Date: 2022-01-20